Leprosy Mailing List – November 27, 2020
Ref.: (LML) Replacing opinions about leprosy treatment with research
From: Vijayaraghavan Radhakrishnan, Chennai, India
________________________________________________________
Dear Pieter,
The LML letter of Dr. Narasimba Rao of November 26, 2020 states that: " Yes, I recommend that we need to study the efficacy of daily dose Rifampicin of 10-20 mg/kg.day (max 600 mg) for 12/24 months (as part of MDT in addition to Dapsone and Clofazimine) in leprosy patients."
I would like to refer to a publication in the Am J Kidney Dis. 2002 Oct;40(4):690-6. doi: 10.1053/ajkd.2002.35675. " Acute renal failure due to rifampicin: a study of 25 patients" (https://pubmed.ncbi.nlm.nih.gov/12324902/)
I may be correct may not be correct, I am not a clinician , I am a Ph.D (Leprosy). I am a non-medical. We have to design a new form of rifampicin like new form of thalidomide (with less genotoxic effect) that will do better.
I am not trying to impose my views, when we consider a disease in terms of clinical approach (ethics comes first), then disinfecting the patient (is the fundamental right of the patient). There are lot of publications that clearly mention the adverse effect of Rifampicin'. Do we need a new clinical multicentre trial to test out this suggestion?
Vijay
Dr. Vijayaraghavan Radhakrishnan. Ph.D (Leprosy),
Chennai (MADRAS)
India
___________________________________________________________________________
LML - S Deepak, B Naafs, S Noto and P Schreuder
LML blog link: http://leprosymailinglist.blogspot.it/
Contact: Dr Pieter Schreuder << edit...@gmail.com
--You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion on the web, visit https://groups.google.com/d/msgid/leprosymailinglist/677e4f40-faab-42fd-b91d-84e0a27ff661n%40googlegroups.com.
No comments:
Post a Comment